Sugi Predict

Sugi Predict / Compounds / SCHEMBL7147808

SCHEMBL7147808

SCHEMBL7147808

CC(=O)N[C@H]1[C@@H](OC(C)=O)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.69
▸ KMT2A Q03164 1/20 0.69
▸ POLB P06746 2/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ CYP3A4 P08684 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ CYP2D6 P10635 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.55
▸ TGM2 P21980 1/20 0.52
▸ CA2 P00918 7/20 0.50
▸ CA1 P00915 6/20 0.50
▸ CA9 Q16790 6/20 0.50
▸ CA12 O43570 5/20 0.50
▸ TSHR P16473 1/20 0.48
▸ NR3C1 P04150 1/20 0.48
▸ FYN P06241 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15333772 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL12847513 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL11223742 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL404573 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL16217766 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL15494655 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL24771437 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL20516514 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL22927890 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL3631711 1.00 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045514-B2 Methods for producing amino-substituted glycolipid compounds DUPONT NUTRITION BIOSCIENCES APS (DK) 2015-06-02 — — US disclosed
US-20120315373-A1 METHODS FOR PRODUCING AMINO-SUBSTITUTED GLYCOLIPID COMPOUNDS DUPONT NUTRITION BIOSCIENCES APS (DK) 2012-12-13 — — US disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 — — US disclosed
US-6353095-B1 OCTULSONIC ACID AND DERIVATIVES WITH AZO AND AMIDE THE SCRIPPS RESEARCH INSTITUTE 2002-03-05 — — US disclosed
EP-0719770-B1 Esculetin derivatives, method for manufacture thereof, and pharmaceutical composition KUREHA CHEMICAL IND CO LTD (JP) 2001-05-09 — — EP disclosed
EP-0860442-B1 Oligosaccharide conjugates and methods of preparation thereof GENZYME CORP (US) 2001-04-18 — — EP disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 — — US disclosed
EP-0654479-B1 Esculetin derivatives and method for manufacture thereof, use thereof, and pharmaceutical composition KUREHA CHEMICAL IND CO LTD (JP) 2000-03-15 — — EP disclosed
EP-0535052-B1 OLIGOSACCHARIDE OXAZOLINES, OLIGOSACCHARIDE CONJUGATES AND METHODS OF PREPARATION THEREOF GENZYME CORP (US) 1998-09-16 — — EP disclosed
EP-0860442-A1 Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof GENZYME CORPORATION (US) 1998-08-26 — — EP disclosed
EP-0719770-A1 Esculetin derivatives, method for manufacture thereof, and pharmaceutical composition Kureha Chemical Industry Co., Ltd. (JP) 1996-07-03 — — EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 — — WO disclosed
EP-0553297-B1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS DU PONT (US) 1995-01-25 — — EP disclosed
US-5288859-A Reacting metal azide with glycosyl phosphate triester E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-02-22 — — US disclosed
US-5241072-A Complexing GENZYNE CORPORATION 1993-08-31 — — US disclosed
EP-0553297-A1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS. DU PONT (US) 1993-08-04 — — EP disclosed
WO-1992009612-A1 PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-06-11 — — WO disclosed
US-5095123-A Phosphorylation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-03-10 — — US disclosed
US-4785084-A REACTION WITH TRIFLUOROMETHANESULFONIC ACID TO FORM PERACETYL OXAZOLINE THE GENERAL HOSPITAL CORPORATION (US) 1988-11-15 — — US disclosed
US-4554349-A Aralkyl and aralkenyl glycosides as inhibitors of antigen-specific T-cell proliferation MERCK & CO., INC. (US) 1985-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120315373-A1 METHODS FOR PRODUCING AMINO-SUBSTITUTED GLYCOLIPID COMPOUNDS AGPAT2, ACMSD, ABHD5 LMNA 2801/4885KMT2A 1747/4885POLB 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback